Andrew N. Schiff, Director at Aclaris Therapeutics, Inc. (ACRS), sold 82,348 shares at $17.01 ($1.4M) on 2022-10-24, disclosed to the SEC on 2022-10-26.
Open-market sale of $1.4M ACRS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.01 | 14,616 | $249K | 17.7% |
| 2 | $17.01 | 14,616 | $249K | 17.7% |
| 3 | $17.02 | 12,018 | $205K | 14.6% |
| 4 | $17.02 | 12,018 | $205K | 14.6% |
| 5 | $17.01 | 14,540 | $247K | 17.7% |
| 6 | $17.01 | 14,540 |
| $247K |
| 17.7% |
| Total | $17.01 avg | 82,348 | $1.4M | 100% |
| Filing → |
| ACRS | SELL | 2022-10-11 | $237K | — | Filing → |
| ACRS | SELL | 2022-10-06 | $1.5M | — | Filing → |
| ACRS | SELL | 2022-06-21 | $592K | — | Filing → |